Search Within

Martin Stuart Tallman

  1. "Ross Levine"
Formats
  1. Meeting Abstract (69)
  2. Journal Article (58)
  3. Research Letter (2)
  4. Guidelines (1)
  5. Review (1)
Groups
  1. Adult Leukemia (131)
  2. Center for Hematologic Malignancies (131)
  3. Department of Medicine (131)
  4. Executive Committee, Center for Hematologic Malignancies (131)
  5. GSK Faculty (131)
  6. Hematologic Malignancies, Division of (131)

More Groups

People
  1. Ross Levine (131)
  2. Omar Abdel-Wahab (44)
  3. Maria Arcila (30)
  4. Eytan Stein (29)
  5. Christopher Famulare (23)
  6. Sean Devlin (23)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2022 (6)
  4. 2021 (7)
  5. 2020 (12)
  6. 2019 (11)

More Years

Publications
  1. Blood (66)
  2. Haematologica (7)
  3. Blood Advances (6)
  4. Leukemia Research (6)
  5. Cancer Discovery (4)
  6. Cancer Research (4)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. Nature Publishing Group (14)
  3. American Association for Cancer Research (8)
  4. Ferrata Storti Foundation (7)
  5. Cell Press (6)
  6. Elsevier Ltd (6)

More Publishers

Results (131)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: A subset analysis from ECOG-ACRIN 1900
    Journal Article

    Fernandez, H. F.; Sun, Z.; Litzow, M. R.; Luger, S. M.; Paietta, E.; Racevskis, J.; Levine, R. L.; Patel, J. P.; Abdel-Wahab, O.; Ketterling, R. P.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
    Journal Article

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Pollyea, D. A.; Stone, R. M.; Altman, J. K.; Roboz, G. J.; Patel, M. R.; Collins, R.; Flinn, I. W.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • PHF6 mutations are mutually exclusive to TP53 mutations, and define a distinct subgroup of secondary acute myeloid leukemia associated with a primitive stem/progenitor immunophenotype, absent complex karyotype and relatively better outcomes
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Ball, B.; Famulare, C.; Pastore, F.; Tallman, M. S.; Zhang, Y.; Arcila, M. E.; Papaemmanuil, E.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for persistent measurable residual disease and poor outcomes in acute myeloid leukemia
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Famulare, C.; Delvin, S.; Patel, M.; McGovern, E.; Patel, A.; Schulman, J.; Dunbar, A.; Epstein-Peterson, Z. D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial
    Meeting Abstract

    Geyer, M. B.; Burke, P. W.; King, A. C.; Mauro, M. J.; Tallman, M. S.; Levine, R. L.; Sherr, C. J.; Douer, D.; Park, J. H.
    Blood (2018)

    Fulltext@MSK | Save
  • Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
    Meeting Abstract

    Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • AML with mutations in IDH1 and DNMT3A exhibits a distinct epigenetic signature with poorer overall survival
    Meeting Abstract

    Ahr, K.; Famulare, C.; Koche, R.; Spitzer, B.; Levine, R. L.; Tallman, M. S.; Goldberg, A. D.; Stein, E. M.; Glass, J. L.
    Blood (2018)

    Fulltext@MSK | Save
  • Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis
    Meeting Abstract

    Bolton, K.; Ptashkin, R.; Braunstein, L.; Kelly, D.; Devlin, S. M.; Coombs, C. C.; Moarii, M.; Patel, M.; Bernard, E.; Berthon, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition
    Journal Article

    Harding, J. J.; Lowery, M. A.; Shih, A. H.; Schvartzman, J. M.; Hou, S.; Famulare, C.; Patel, M.; Roshal, M.; Do, R. K.; Zehir, A.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity
    Journal Article

    Kunimoto, H.; Meydan, C.; Nazir, A.; Whitfield, J.; Shank, K.; Rapaport, F.; Maher, R.; Pronier, E.; Meyer, S. C.; Garrett-Bakelman, F. E.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save